Proteinuria Treatment Market Forecast and Segments, 2016-2026
Proteinuria is also called as albuminuria is a condition in which urine contains abnormal (excessive) amount of protein. It is a disease which results from damage within the kidneys. The kidney performs filtration of waste, minerals and fluids from the blood to the urine. When kidneys do not perform filtration properly that results an abnormal (excessive) amount of proteins (albumin and globulin) excrete through the urine. Sign and symptom of proteinuria includes edema present in face, arms, hands, abdomen and hypertension with foamy urine. Risk factors for proteinuria includes, diabetes and hypertension (high blood pressure) mostly and sometimes obesity and age over 65.
American Diabetic Association stated that people with high blood pressure and diabetes are at high risk for developing proteinuria. Thus, increase in diabetic and hypertensive patients worldwide are the main driving factors for the growth of proteinuria treatment market. Kidney disease often has no early symptoms. Hence, lack of awareness among people about proteinuria is expected to restrain the growth of global proteinuria treatment market.
Proteinuria Treatment Market: Drivers and Restraints
Types of proteinuria includes Transient and Orthostatic proteinuria. Proteinuria can be caused by diseases not involving the kidneys, such as multiple myeloma, a cancer of the plasma cells in the bone marrow. In diabetes, the main causes of proteinuria are high blood glucose levels over a period of years. Pre-eclampsia, a condition which can affect pregnant women, includes very high blood pressure and is another potential cause of protein in the urine.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1486
Proteinuria Treatment Market: Segmentation
Proteinuria treatment market can be segmented on the basis of drug type, distribution channel and geography.
Based on drug type, proteinuria treatment market can be segmented as follows:
- ACE inhibitors (angiotensin-converting enzyme inhibitors)
- ARBs (angiotensin receptor blockers)
- DPP (dipeptidyl peptidase) IV inhibitors
- Based on distribution channel, proteinuria treatment market can be segmented as follows:
- Hospitals including hospital pharmacies
- Retail Pharmacies
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1486
Proteinuria Treatment Market: Overview
Proteinuria can be diagnosed by urine albumin to creatinine ratio (UACR) test, glomerular filtration rate (GFR) test, renal ultrasound scan, and kidney biopsy test. Since proteinuria is a symptom and not a disease itself, medical care focuses on treating the underlying condition, such as normalizing blood pressure in people with hypertension or controlling blood sugar levels in those with diabetes. However, drugs are even prescribed for people with diabetes and high blood pressure.
Proteinuria Treatment Market: Region-wise Outlook
Region wise, the global proteinuria treatment marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominates the global market for proteinuria treatment due to high prevalence rate of diabetes and hypertension among North American population. Moreover, technological advancements in diagnostic test further accentuates the market growth in this region. Europe holds the second position in proteinuria treatment owing to its large geriatric population base (people above 65 years of age). Asia-pacific holds the third and fourth position in the global proteinuria treatment market due to lack of sufficient healthcare facilities (diagnostic test).
Proteinuria Treatment Market: Key Players
Some of the key players contributing to the global proteinuria treatment market includes Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc., Reddys Lab, and Novartis AG.